Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent and overdose-prevention drug formulations for the prescription medication market. The company entered public markets in 2021 through a SPAC merger, targeting the healthcare and life sciences sector and listing on the Nasdaq Capital Market under the ticker ENSC. On January 17, 2024, Ensysce filed a Form S-1 registration statement with the Securities and Exchange Commission, accession number 0001493152-24-002548, reflecting ongoing capital-markets activity as a post-combination public company. Its pipeline centers on proprietary opioid formulations engineered to resist misuse and reduce overdose risk. Sign up on SpacDesk for complete filing history, deal analytics, and real-time monitoring on ENSC and hundreds of other SPAC transactions.